XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Income taxes
6 Months Ended
Jun. 30, 2020
Income taxes
NOTE 11 – Income taxes:
In the second quarter of 2020, Teva recognized a tax benefit of $104 million, on
pre-tax
loss of $51 million. In the second quarter of 2019, Teva recognized a tax benefit of $179 million, on
pre-tax
loss of $850 million. Teva’s tax rate for the second quarter of 2020 was mainly affected by impairments in jurisdictions in which tax rates are higher than Teva’s average tax rate on its ongoing business operations
 
and other changes to tax positions and deductions.
In the first six months of 2020, Teva recognized a tax benefit of $163 million, on
pre-tax
loss of $84 million. In the first six months of 2019, Teva recognized a tax benefit of $170 million, on
pre-tax
loss of $934 
million. Teva’s tax rate for the first six months of 2020 was mainly affected by impairments reflected in the quarter in jurisdictions in which tax rates are higher than Teva’s average tax rate on its ongoing business operations and other changes to tax positions and deductions.
The statutory Israeli corporate tax rate is 23% in 2020.
Teva’s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits in Israel and other countries, as well as infrequent or discrete items.
Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in September 2020. A final and binding decision against Teva in this case may lead to an impairment of $136 million.
The Israeli tax authorities issued a tax assessment decrees for 2013-2016, challenging the Company’s positions on several issues.
Teva will protest the 2013-2016 decrees before the Central District Court in Israel. The Company believes it has adequately provided
for these items, however, an adverse result could be material.